VictorGurewichMD
Internal Medicine • Cambridge, MACardiology
Professor of Medicine, Mt. Auburn Hospital
Dr. Gurewich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Mount Auburn St
305
Cambridge, MA 02138Phone+1 617-661-0567Fax+1 617-876-0524- Is this information wrong?
Education & Training
Boston VA Healthcare System (Brockton-West Roxbury)Fellowship, Cardiovascular Disease, 1960 - 1961
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1959 - 1960- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1956 - 1957
- Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1955 - 1956
Harvard Medical SchoolClass of 1955
Certifications & Licensure
MA State Medical License 1960 - 2023- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 5 citationsDual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase...Nadinda A M van der Ende, Bob Roozenbeek, Lucas E M Smagge, Sven P R Luijten, Leo A M Aerden, Petra Kraayeveld, Ido R van den Wijngaard, Geert J Lycklama À Nijeholt, H...> ;Trials. 2022 Aug 9
- 2 citationsFibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is UnknownVictor Gurewich> ;Cardiovascular Drugs and Therapy. 2019 Dec 1
- 1 citationsA first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: comment.Victor Gurewich, Ralph Pannell> ;Journal of Thrombosis and Haemostasis. 2017 Aug 11
- Join now to see all
Press Mentions
Thrombolytic Science Granted US Patent on Novel Clot Dissolving Therapy, Complementing Patent Protection in Europe, Japan, China, Hong Kong, Mexico & CISOctober 29th, 2021
TSI Reports Enrollment of First 10 Patients in Its Phase 2 Ischemic Stroke Clinical Trial and Completion of Its Phase 2 Study Protocol in Myocardial InfarctionOctober 30th, 2019
Brilinta Gatekeepers; Costly Caregiving; Renal Denervation TrialApril 9th, 2018- Join now to see all
Grant Support
- Purification And Properties Of High Affinity UrokinaseNational Heart, Lung, And Blood Institute1985–1986
Hospital Affiliations
Mount Auburn HospitalCambridge, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
